Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: Sensitivity and specificity

Nephrology Dialysis Transplantation

Volumn 22, Issue 4, 2007, Pages 1156-1162

  Bovy, Christophe ^a   Gothot, André ^a   Delanaye, Pierre ^a   Warling, Xavier ^b   Krzesinski, Jean Marie ^a   Beguin, Yves ^a  

^a CHU SART TILMAN   (Belgium)

^b CHR Citadelle ^*  (Belgium)

Author keywords

Anaemia; Haemodialysis; Iron monitoring; Mature erythrocyte parameters; Percentage of hypochromic red blood cells

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG RESPONSE; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; PREDICTION; PRIORITY JOURNAL; RETICULOCYTE HEMOGLOBIN CONTENT; ROC CURVE; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ANEMIA, HYPOCHROMIC; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; ERYTHROCYTE COUNT; ERYTHROCYTES; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 34047180595     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl765     Document Type: Article

References (24)

1. Evans RW, Rader B, Manninen DL. Cooperative multicenter EPO clinical trial group: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263: 825-830
2. Delano BG. Improvement in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14: 14-18
3. Grutzmacher P, Scheuermann E, Low I et al. Correction of renal anaemia with recombinant human erythropoietin: Effects on myocardial function. Contrib Nephrol 1988; 66: 176-184
4. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20: 345-349
5. Fletes R, Lazarus JM, Gage J et al. Suspected iron dextranrelated adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37: 745-749
6. Ahlmén J, Vaage-Nilsen O. Safety evaluation of iron (Ferlecit®, DexFerrum®, INFeD®) from 21,060,000 doses administered I.V. in the US 1998-2000. Nephrol Dial Transplant 2002; 17[Suppl 1]: 133
7. Zanen AL, Adriaansen HJ, van Bommel EFH et al. Oversaturation of transferin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824
8. Zager RA, Johnson ACM, Hanson Sy et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
9. Tovbin D, Mazor D, Vorobiov M et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 2002; 40: 1005-1012
10. Teehan GS, Bahdouch D, Ruthazer R et al. Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 15: 1090-1094
11. Canziani ME, Yumiya ST, Rangel EB et al. Risk of bacterial infection in patients under intravenous iron therapy: Dose versus length of treatment. Artif Organs 2001; 25: 866-869
12. Hoen B, Paul-Dauphin A, Hestin D et al. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 8: 869-876
13. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423
14. Bovy C, Tsobo L, Crapanzano L et al. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Kidney Int 1999; 56: 1113-1119
15. Bovy C, Krzesinski JM, Gothot A et al. Impact of erythropoietic activity on red cell parameters in chronic renal failure patients. Haematologica 2004; 89: 748-749
16. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2005; 20: 1512-3.
17. National Kidney Foundation DOQI, Am J Kidney Dis 1997; 30 [Suppl 3]: S218-S220.
18. Hörl WH, Dreyling K, Steinhauer HB et al. Iron status of dialysis patients under rhuEPO therapy. Contrib Nephrol 1990; 87: 78-86
19. Brugnara C, Collela GM, Cremins J et al. Effects of subcutaneous recombinant erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994; 123: 660-667
20. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
21. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46
22. Hakim RM, Stivelman JC, Schulman G et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987; 10: 293-299
23. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 2001; 38: 109-117
24. Bovy C, Gothot A, Krzesinski JM et al. Mature erythrocyte indices: New markers of iron availability. Haematologica 2005; 90: 549-551